Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(30)
Filter by content year
(-)
2023
(30)
Filter by form group
Filter by category
(-)
Other
(30)
Collaborators
(11)
Events
(10)
Financial
(8)
Science
(2)
Filter by category
Search
News
BioNTech kündigt strategische Partnerschaft mit der Regierung des Vereinigten Königreichs an, um bis 2030 bis zu 10.000 Patientinnen und Patienten mit personalisierten mRNA-Krebsimmuntherapien zu behandeln
News
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
News
BioNTech kündigt Übernahme von InstaDeep an, um Vorreiterrolle auf dem Gebiet KI-basierter Arzneimittelforschung, -design und -entwicklung zu stärken
News
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
News
BioNTech stärkt Produktionsstandort Marburg durch erste unternehmenseigene Plasmid-DNA-Herstellungsstätte
News
BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
News
Statement zur humanitären Hilfe in der Türkei, Syrien und der Ukraine
News
Statement on Humanitarian Aid in Türkiye, Syria and Ukraine
News
Pfizer und BioNTech beginnen Phase-1/2-Studie mit erstem mRNA-basierten Impfstoffprogramm gegen Gürtelrose
News
Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program
Pagination
Page 1
Next page
››